H. U. Schorlemmer

2.6k total citations
110 papers, 2.1k citations indexed

About

H. U. Schorlemmer is a scholar working on Molecular Biology, Immunology and Surgery. According to data from OpenAlex, H. U. Schorlemmer has authored 110 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Molecular Biology, 34 papers in Immunology and 20 papers in Surgery. Recurrent topics in H. U. Schorlemmer's work include Monoclonal and Polyclonal Antibodies Research (13 papers), Biochemical and Molecular Research (12 papers) and Complement system in diseases (10 papers). H. U. Schorlemmer is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (13 papers), Biochemical and Molecular Research (12 papers) and Complement system in diseases (10 papers). H. U. Schorlemmer collaborates with scholars based in Germany, United States and United Kingdom. H. U. Schorlemmer's co-authors include A. C. Allison, R. Kurrle, D Bitter-Suermann, R. R. Bartlett, J. Ferluga, Klaus Bosslet, Hans Prydz, P.A. Davies, C. Arden Pope and Edward Keystone and has published in prestigious journals such as Nature, The Lancet and British Journal of Cancer.

In The Last Decade

H. U. Schorlemmer

101 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
H. U. Schorlemmer Germany 27 751 608 307 266 217 110 2.1k
Susumu Miyata Japan 20 431 0.6× 890 1.5× 247 0.8× 245 0.9× 118 0.5× 29 2.2k
Ina Fabian Israel 29 557 0.7× 683 1.1× 236 0.8× 421 1.6× 366 1.7× 91 2.0k
Peter Oliver United States 25 1.6k 2.1× 1.0k 1.7× 372 1.2× 320 1.2× 264 1.2× 44 3.6k
C.E. Orfanos Germany 31 1.1k 1.5× 1.1k 1.7× 118 0.4× 327 1.2× 168 0.8× 113 2.9k
René Moser Switzerland 25 992 1.3× 431 0.7× 229 0.7× 175 0.7× 133 0.6× 47 2.2k
Jeehee Youn South Korea 32 1.2k 1.5× 780 1.3× 195 0.6× 329 1.2× 212 1.0× 86 2.5k
R M Marks United States 13 1.1k 1.4× 862 1.4× 124 0.4× 330 1.2× 117 0.5× 17 2.2k
Marta L. Corcoran United States 21 548 0.7× 765 1.3× 135 0.4× 706 2.7× 271 1.2× 27 2.5k
W R Benjamin United States 22 1.4k 1.9× 600 1.0× 152 0.5× 340 1.3× 144 0.7× 33 2.4k
Takeshi Yoshida United States 30 1.4k 1.8× 629 1.0× 124 0.4× 253 1.0× 94 0.4× 122 2.5k

Countries citing papers authored by H. U. Schorlemmer

Since Specialization
Citations

This map shows the geographic impact of H. U. Schorlemmer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. U. Schorlemmer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. U. Schorlemmer more than expected).

Fields of papers citing papers by H. U. Schorlemmer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. U. Schorlemmer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. U. Schorlemmer. The network helps show where H. U. Schorlemmer may publish in the future.

Co-authorship network of co-authors of H. U. Schorlemmer

This figure shows the co-authorship network connecting the top 25 collaborators of H. U. Schorlemmer. A scholar is included among the top collaborators of H. U. Schorlemmer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. U. Schorlemmer. H. U. Schorlemmer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schorlemmer, H. U.. (2001). Development of a novel drug for transplantation: current results and future perspectives. Transplantation Proceedings. 33(3). 2425–2428. 6 indexed citations
2.
Schorlemmer, H. U., R. R. Bartlett, & R. Kurrle. (1999). Malononitrilamides prevent the generation of oxygen radicals in mononuclear phagocytes and graft rejection in a rat model. Transplantation Proceedings. 31(1-2). 851–853. 4 indexed citations
3.
Schorlemmer, H. U., et al.. (1999). MALONONITRILAMIDES (MNAs) EXERT THEIR IMMUNOSUPPRESSIVE ACTIVITY PRIMARILY BY INHIBITION OF DIHYDROOROTATE DEHYDROGENASE (DHODH).. Transplantation. 67(7). S60–S60. 1 indexed citations
4.
Schorlemmer, H. U., R. Kurrle, R. Schleyerbach, & R. R. Bartlett. (1999). Generation of O 2 - radicals in macrophages can be inhibited in vitro and in vivo by derivatives of leflunomide's primary metabolite. Inflammation Research. 48(0). 117–118. 3 indexed citations
5.
Schorlemmer, H. U., et al.. (1999). Cell cycle regulation and inhibition of de novo pyrimidine biosynthesis by leflunomide. Inflammation Research. 48(0). 115–116. 3 indexed citations
6.
Schorlemmer, H. U., R. R. Bartlett, & R. Kurrle. (1998). Inhibition of Alloreactivity in the Popliteal Lymph Node Assay by Malononitrilamides. Transplantation Proceedings. 30(4). 968–970. 1 indexed citations
7.
Schwab, W., et al.. (1998). A MOLECULAR MECHANISM FOR THE DIRECT ANTIPROLIFERATIVE EFFECT OF MALONONITRILAMIDES (MNAs) ON VASCULAR SMOOTH MUSCLE CELLS.. Transplantation. 65(Supplement). 115–115. 4 indexed citations
8.
Schorlemmer, H. U. & R. Kurrle. (1997). Long-term xenograft survival by combination therapy of malononitrilamide MNA 715 with cyclosporine. Transplantation Proceedings. 29(8). 3501–3504. 5 indexed citations
9.
Schorlemmer, H. U. & R. Kurrle. (1997). Various graft vs. host diseases (GvHD) in rodents can be prevented and treated by malononitrilamides (MNAs). Inflammation Research. 46(0). 165–166. 13 indexed citations
10.
Schorlemmer, H. U. & R. Kurrle. (1996). Control of mouse-to-rat skin xenograft rejection by malononitrilamides.. PubMed. 28(6). 3037–9. 6 indexed citations
11.
Schorlemmer, H. U., et al.. (1996). Effect of malononitrilamides on human bone marrow.. PubMed. 28(6). 3051–2. 3 indexed citations
12.
Schorlemmer, H. U., et al.. (1996). Acute skin graft rejection can be prevented and treated in rat models by malononitrilamides.. PubMed. 28(6). 3048–50. 8 indexed citations
13.
Schorlemmer, H. U. & Gerhard Dickneite. (1994). Disease modifying activity of 15-deoxyspergualin on acute and chronic relapsing experimental allergic encephalomyelitis as models of multiple sclerosis (MS). Inflammation Research. 41(S2). C209–C211. 1 indexed citations
14.
Menger, MD, et al.. (1990). New immunosuppressive agents in experimental allogeneic heart transplantation.. PubMed. 22(5). 2324–2324. 1 indexed citations
15.
Reichenspurner, Hermann, Paul Human, Dieter H. Boehm, et al.. (1990). 15-DEOXYSPERGUALIN FOR INDUCTION OF GRAFT NONREACTIVITY AFTER CARDIAC AND RENAL ALLOTRANSPLANTATION IN PRIMATES. Transplantation. 50(2). 181–185. 31 indexed citations
16.
17.
Schorlemmer, H. U., et al.. (1981). Macrophage Activation by Various Stimuli Is Mediated by Endogenous C3. International Archives of Allergy and Immunology. 66(Suppl. 1). 183–187. 6 indexed citations
18.
Bitter-Suermann, D, Stefan Becker, Stefan Meuer, et al.. (1980). Comparative study on biological effects of the guinea pig complement-peptide C3a and C3a-related synthetic oligopeptides. Molecular Immunology. 17(10). 1257–1261. 13 indexed citations
19.
Ferluga, J., et al.. (1978). Production of the complement cleavage product, C3a, by activated macrophages and its tumorolytic effects.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 31(3). 512–7. 91 indexed citations
20.
Schorlemmer, H. U., D Bitter-Suermann, & A. C. Allison. (1977). Complement activation by the alternative pathway and macrophage enzyme secretion in the pathogenesis of chronic inflammation.. PubMed. 32(6). 929–40. 103 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Susumu Miyata Breakdown of academic impact, for papers by Ina Fabian Breakdown of academic impact, for papers by Peter Oliver Breakdown of academic impact, for papers by C.E. Orfanos Breakdown of academic impact, for papers by René Moser Breakdown of academic impact, for papers by Jeehee Youn Breakdown of academic impact, for papers by R M Marks Breakdown of academic impact, for papers by Marta L. Corcoran Breakdown of academic impact, for papers by W R Benjamin Breakdown of academic impact, for papers by Takeshi Yoshida
Rankless by CCL
2026